QQQ   437.06 (-0.23%)
AAPL   182.63 (-0.94%)
MSFT   410.69 (-0.23%)
META   484.52 (-0.33%)
GOOGL   144.04 (-0.03%)
AMZN   174.94 (+0.21%)
TSLA   192.20 (-2.64%)
NVDA   789.51 (+0.53%)
NIO   5.41 (-7.52%)
AMD   176.78 (-2.79%)
BABA   75.94 (-0.24%)
T   16.82 (+1.39%)
F   12.16 (+0.33%)
MU   86.15 (+0.28%)
CGC   3.37 (+0.00%)
GE   153.34 (+1.10%)
DIS   107.86 (+0.20%)
AMC   4.46 (+0.90%)
PFE   27.79 (+0.87%)
PYPL   59.24 (+1.53%)
XOM   103.93 (-0.79%)
QQQ   437.06 (-0.23%)
AAPL   182.63 (-0.94%)
MSFT   410.69 (-0.23%)
META   484.52 (-0.33%)
GOOGL   144.04 (-0.03%)
AMZN   174.94 (+0.21%)
TSLA   192.20 (-2.64%)
NVDA   789.51 (+0.53%)
NIO   5.41 (-7.52%)
AMD   176.78 (-2.79%)
BABA   75.94 (-0.24%)
T   16.82 (+1.39%)
F   12.16 (+0.33%)
MU   86.15 (+0.28%)
CGC   3.37 (+0.00%)
GE   153.34 (+1.10%)
DIS   107.86 (+0.20%)
AMC   4.46 (+0.90%)
PFE   27.79 (+0.87%)
PYPL   59.24 (+1.53%)
XOM   103.93 (-0.79%)
QQQ   437.06 (-0.23%)
AAPL   182.63 (-0.94%)
MSFT   410.69 (-0.23%)
META   484.52 (-0.33%)
GOOGL   144.04 (-0.03%)
AMZN   174.94 (+0.21%)
TSLA   192.20 (-2.64%)
NVDA   789.51 (+0.53%)
NIO   5.41 (-7.52%)
AMD   176.78 (-2.79%)
BABA   75.94 (-0.24%)
T   16.82 (+1.39%)
F   12.16 (+0.33%)
MU   86.15 (+0.28%)
CGC   3.37 (+0.00%)
GE   153.34 (+1.10%)
DIS   107.86 (+0.20%)
AMC   4.46 (+0.90%)
PFE   27.79 (+0.87%)
PYPL   59.24 (+1.53%)
XOM   103.93 (-0.79%)
QQQ   437.06 (-0.23%)
AAPL   182.63 (-0.94%)
MSFT   410.69 (-0.23%)
META   484.52 (-0.33%)
GOOGL   144.04 (-0.03%)
AMZN   174.94 (+0.21%)
TSLA   192.20 (-2.64%)
NVDA   789.51 (+0.53%)
NIO   5.41 (-7.52%)
AMD   176.78 (-2.79%)
BABA   75.94 (-0.24%)
T   16.82 (+1.39%)
F   12.16 (+0.33%)
MU   86.15 (+0.28%)
CGC   3.37 (+0.00%)
GE   153.34 (+1.10%)
DIS   107.86 (+0.20%)
AMC   4.46 (+0.90%)
PFE   27.79 (+0.87%)
PYPL   59.24 (+1.53%)
XOM   103.93 (-0.79%)
NASDAQ:KITE

(KITE) (KITE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$179.79
$179.79
50-Day Range
N/A
52-Week Range
$39.82
$179.99
Volume
N/A
Average Volume
1.65 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

KITE stock logo

About (KITE) Stock (NASDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).


KITE Stock News Headlines

AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Q4 2023 Kite Realty Group Trust Earnings Call
Piper Sandler Reaffirms Their Buy Rating on Kite Realty Group (KRG)
Sell Rating on Kite Realty Group Amid Growth and Credit Concerns
Kite Realty declares $0.25 dividend
See More Headlines
Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2017
Today
2/23/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:KITE
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Arie S. Belldegrun
    Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson
    Chief Financial Officer
  • Cynthia M. Butitta
    Chief Operating Officer
  • David Chang M.D. Ph.D.
    Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim
    Executive Vice President - Business Development
  • Timothy L. Moore
    Executive Vice President - Technical Operations
  • Christine Cassiano
    Senior Vice President - Corporate Communications and Investor Relations

  • Bio & Compensation - 
  • Jian Irish Ph.D.
    Senior Vice President - Supply Chain

  • Bio & Compensation - 
  • Jeffrey Wiezorek M.D.
    Senior Vice President - Clinical Development
  • Shawn Cline Tomasello
    Chief Commercial Officer














KITE Stock Analysis - Frequently Asked Questions

How were (KITE)'s earnings last quarter?

(KITE) (NASDAQ:KITE) released its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, topping analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to analysts' expectations of $5.74 million. The firm's revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.54) EPS.

What other stocks do shareholders of (KITE) own?
This page (NASDAQ:KITE) was last updated on 2/23/2024 by MarketBeat.com Staff